NDAORALFOR SUSPENSION, EXTENDED RELEASE
Approved
Sep 2012
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
13
Data completeness
6/8 — Strong
QUILLIVANT XR (methylphenidate hydrochloride) by Teva is (cns) stimulant. Approved for attention deficit hyperactivity disorder. First approved in 2012.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QUILLIVANT XR is an extended-release oral suspension of methylphenidate hydrochloride, a CNS stimulant approved for ADHD and off-label use in cancer-related fatigue and anxiety disorders. It works by blocking the reuptake of norepinephrine and dopamine, increasing their availability in the extraneuronal space. The suspension formulation offers flexibility in dosing for patients who cannot swallow tablets.
$0.196MPart D
Peak4.8 years to LOEProduct is in peak lifecycle stage with modest Medicare spending, indicating mature market position with moderate commercial team engagement.
Mechanism of Action
(CNS) stimulant. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. Methylphenidate is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.
Indications (1)
Clinical Trials (13)
A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
Started Apr 2019
60 enrolled
Attention Deficit Hyperactivity DisorderGeneralized Anxiety DisorderSocial Anxiety Disorder+2 more
Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
Started Sep 2014
36 enrolled
ADHDAutism
Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder
Started Apr 2011
299 enrolled
Attention Deficit/Hyperactivity Disorder
Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)
Started Nov 2010
725 enrolled
Attention Deficit/Hyperactivity Disorder
Adult Study / OROS Methylphenidate Hydrochloride (HCL) (OROS MPH) in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Started Jul 2009
357 enrolled
Attention Deficit Disorder With Hyperactivity
Worked on QUILLIVANT XR at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.